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Summary Serum aminoglutethimide (AG) and N-acetylaminoglutethimide (NAG) concentrations were
measured by high pressure liquid chromatography (HPLC) in 24 postmenopausal women with advanced
breast cancer receiving increasing doses of oral AG. Patients received 62.5mg b.d., 125mg b.d., 250mg b.d.,
and 500mg b.d. of AG alone, and 500mg b.d. of AG combined with hydrocortisone (HC) 20mg b.d. Dose
was increased at monthly intervals. Each dose increment was accompanied by a significant rise in serum AG
and NAG levels (P<0.05). The addition of HC to the dose of 500mg b.d. of AG did not alter serum AG or
NAG concentrations significantly. Although serum AG and NAG levels appeared to increase linearly with
dose, serum NAG increased significantly more slowly, leading to a fall in the NAG:AG ratio during therapy.
The NAG:AG ratio appeared to stabilise only after about 6 months of treatment.
Aminoglutethimide (AG), in a dose of 1 g daily
combined with hydrocortisone (HC), is effective in
the treatment of advanced postmenopausal breast
cancer (Smith et al., 1978; Harris et al., 1982);
Santen et al., 1982) and has been assumed to act as
a "medical adrenalectomy". Adrenal suppression is
achieved principally through inhibition of the
desmolase enzyme system (Kahnt & Neher, 1966;
Cash et al., 1967) responsible for the conversion of
cholesterol to pregnenolone. However, AG also
inhibits the peripheral aromatase enzyme system
(Graves & Salhanick, 1979; Brodie, 1982; Santen et
al., 1978), believed to be the major source of
oestrone synthesis in postmenopausal women
(MacDonald et al., 1967; Grodin et al., 1973).
In vitro studies suggest that aromatase inhibition
is achieved by lower doses of AG than necessary
for desmolase inhibition (Graves & Salhanick, 1979;
Santen & Misbin, 1981; Harris et al., 1983) and
thus, aromatase inhibition rather than adrenal sup-
pression may be the underlying mechanism of
oestrogen suppression by AG. For this reason, and
as the side effects of AG have been reported to be
dose-related (Murray et al., 1979), several inves-
tigators have recently assessed the use of low dose
AG, without a glucocorticoid as a method of
ostrogen suppression (Stuart-Harris et al., 1985;
Harris et al., 1983; Vermeulen et al., 1983).
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To date, there are only limited data concerning
the metabolism and pharmacokinetics of AG. After
oral administration of 0.1-I.Og of AG, 35-54% of
the dose is excreted unchanged in the urine within
48 hours (Douglas & Nicholls, 1965, 1972). N-
acetylaminoglutethimide (NAG) has been identified
as the major metabolite, and 4-25% of an oral dose
of AG is excreted as urinary NAG within 48h.
Acetylation is phenotype dependent with signifi-
cantly higher levels of NAG achieved by fast acety-
lators (Coombes et al., 1980). Peak plasma AG
levels of 5.6-6.3 4ugml-1 have been observed 0.7-
1.5h after 500mg AG given to healthy volunteers
(Thompson et al., 1981): an initially rapid decline in
plasma concentration of the drug occurs, followed
by a slower decline with a half-life of 10-15h.
Although serum levels of AG have been
examined in postmenopausal breast cancer patients
receiving conventional doses of AG combined with
HC (Murray et al., 1979), there has been no
previous study of drug levels during conventional
dose AG without HC, or during low dose AG
therapy alone with or without HC.
Materials and methods
Patients
After approval from the Medical Ethics Committee
ofthe Royal Marsden Hospital and informed patient
consent, 33 postmenopausal women with advanced
breast cancer participated in the study. All were
more than two years from their last menstrual
period; mean age was 64 years (range 46-77 years).
None had evidence of renal or hepatic dysfunction
as measured by standard biochemical parameters.486 R. STUART-HARRIS et al.
Drug dosage and blood samples
Increasing oral doses of AG were used during the
study, with dose increments at monthly intervals.
During the first month patients received 62.5 mg
twice daily (b.d.), during the second month 125mg
b.d., during the third month 250 mg b.d., and
during the fourth month 500mg b.d. During the
fifth and subsequent months of the study patients
received combined AG (500 mg b.d.) and HC
(20 mg b.d.) therapy. The clinical results (Stuart-
Harris et al., 1984) and oestrogen suppression
obtained in these patients at each dosage (Stuart-
Harris et al., 1985) have been reported elsewhere.
Five ml serum samples were collected from
patients prior to entry and at monthly intervals
during the study. As AG has been reported to be
stable when frozen, serum samples were stored at
-20°C until analysis (Thompson et al., 1981). For
each sample the following information was noted:
(1) Dose of AG.
(2) Time of last dose.
(3) Time of blood sample.
(4) Concomitant drug therapy.
(5) Duration of therapy.
Measurement of AG and NAG levels
Serum AG and NAG levels were measured by high
pressure liquid chromatography, the method for
which is described fully elsewhere (Adam et al.,
1984). Briefly, a 30cm by 4mm reversed-phase
Lichrosorb column (5gm, RP8) with a mobile
phase of 42:58 methanol/water at a flow rate of
0.9mlmin- 1 were used. Serum samples were
thawed and after thorough mixing, 0.5ml pipetted
into 1Oml stoppered glass centrifuge tubes. Fifteen
jl internal standard (l00yjgml-' phenacetin in
methanol), 0.5ml of acetate buffer (pH 6.0), and 3ml
of dichloromethane were then added to the samples
which were extracted on a rollermixer for 15min.
Following centrifugation for 5min, the upper
aqueous layer was carefully removed and discarded
while the lower organic layer was transferred to a
further centrifuge tube and evaporated in a water
bath at 400C under a stream of nitrogen. The
residue was dissolved in 120jl of the mobile phase
and 20pl taken and injected into the chromato-
graph.
Serum samples containing known concentrations
of AG and NAG were treated in a similar manner
and a standard curve prepared by plotting the peak
height of drug against internal standard concen-
tration. The inter-assay coefficient of variation for
AG was 14.3% at ljigml-P, 9.1% at 3jigml-P and
6.9% at 8 jgml- 1 and for NAG 8.3% at
0.5ugml-1, 4.4% at 2.0pgml-' and 4.8% at
4.0/,tgml-'. The intra-assay coefficient of variation
for AG was 2.5% at 2ugml', 2.7% at 5pgml-1
and 10.5% at 10igml-1 and for NAG 1.9% at
0.5pgml-', 1.0% at lugml-' and 0.7% at
3 jugml-'.
Analysis ofdata
Because of variation in the time intervals between
drug administration and blood sampling, data were
selected so that the only samples described in this
report were those for which the interval between
dose and blood collection was +1 hour of the usual
interval for each patient. With this selection, data
were available for 24 of 33 patients..
Statistical analysis
Serum concentrations of AG and NAG at the
different doses were compared using paired t-tests,
adjusted with the Bomferroni correction for mul-
tiple comparisons (Cupples et al., 1984). Linear
regression analysis (Dixon, 1981) was used to com-
pare the concentrations of AG and NAG at each
dosage.
Results
Serum AG and NAG concentrations and the resul-
tant NAG:AG ratios at each dosage are shown in
Tables I, II and III, respectively. Mean serum AG
and NAG concentrations plotted against dose are
shown in Figures 1 and 2. The time intervals
between drug administration and blood samples are
shown in Table IV.
Statistical analysis using paired t-tests revealed
that each dose increment was accompanied by a
significant rise in both AG and NAG concen-
trations (P<0.05). However no significant alteration
in AG or NAG concentration occurred when HC
was added to the dose of 500mg b.d. of AG. Both
AG and NAG concentrations appeared to increase
in approximate linear relationships with dose
(r=0.982 and 0.948, Figures 1 and 2 respectively).
Linear regression analysis revealed that the
regression lines for AG and NAG at the various
dose levels (Figures 1 and 2, respectively) were
significantly different (P<0.0001). NAG concen-
trations increased significantly more slowly than AG,
leading to a decline in the NAG:AG ratio observed
at higher doses (Table III). Although sequential
dose increments were not accompanied by a signifi-
cant fall in NAG:AG ratios, the ratios at the dose
of 500mg b.d. of AG plus HC were significantly
lower than at 62.5mg b.d. of AG (P=0.003, paired
t-test).Table I Serum concentration of AG (pgml-') in 24 patients receiving increasing doses
of AG. (AG Aminoglutethimide; HC=Hydrocortisone; b.d.=twice daily).
Dose ofAG (mg)
Patient 62.5 125 250 500 500
No. b.d. b.d. b.d. b.d. b.d.+HC
Serum AG concentration (Mgml-1)
1 0.1 0.8 9.1
3 0.6 1.3 3.0
4 0.7 8.4
5 0.7 2.3 1.4
7 2.6 8.2 8.0
8 0.2 0.9 2.5 8.2 7.1
9 0.7 0.9 4.6 9.4 12.8
10 0.5 8.5 7.1
12 0.7 8.1
15 2.0 4.5 16.9 15.5
16 1.6 4.1 10.2
17 0.2 3.2 9.5
19 0.4 0.3 3.1 1.2 7.2
21 0.6 1.4 3.1 8.0 10.8
22 0.6 1.6 2.7
23 0.4 2.7 3.0 6.8 7.6
25 0.2 1.8 7.3 6.4
26 0.6 1.7 11.3
29 1.0 2.3
30 0.3 0.9 2.5 -
31 1.0 2.4 2.7
32 0.9 18.2 21.3
33 0.2 1.4 3.5 2.9
34 0.7 1.5 -
No. of samples =18 17 18 14 14
Mean = 0.47 1.47 3.50 8.42 9.09
S.e. of the mean = 0.05 0.18 0.59 1.26 1.30
No. of
paired samples 13 13 11 12
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Figure 1 Mean serum aminoglutethimide concen-
tration versus dose in 24 patients receiving increasing
doses ofaminoglutethimide. (Error bars represent s.e.m.;
N =Number of patients at each dose.)
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Figure 2 Mean serum N-acetylaminoglutethimide
concentration versus dose in 24 patients receiving
increasing doses of aminoglutethimide. (Error bars
represent s.e.m.; N=Number of patients at each dose.)
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Table II Serum concentrations of NAG (pgml-1) in 24 patients receiving increasing
doses of AG. (NAG=N-acetylaminoglutethimide; AG=aminoglutethimide; HC=hydro-
cortisone; b.d. =twice daily).
Dose ofAG (mg)
Patient 62.5 125 250 500 500
No. b.d. b.d. b.d. b.d. b.d. +HC
Serum NAG concentration (pgml-)
1 0.2 0.4 1.3
3 0.3 0.6 0.9
4 0.8 3.6
5 0.6 0.8 1.0
7 0.8 1.5 1.9
8 0.7 1.3 2.1 3.3 3.5
9 0.5 0.8 1.2 1.5 2.6
10 1.3 4.9 4.7
12 0.6 2.0
15 1.2 1.5 2.5 1.9
16 0.6 1.1 1.7
17 0.1 1.0 - 1.4
19 0.7 1.0 2.4 2.9 3.1
21 0.2 0.5 0.7 1.2 1.2
22 0.4 0.5 0.6
23 0.4 1.0 1.3 1.3 1.1
25 0.4 1.5 2.7 2.5
26 0.2 0.4 1.4
29 2.3 3.6
30 1.5 2.4 4.0
31 0.7 0.8 0.9
32 - 1.5 3.7 4.2
33 0.3 1.6 2.5 3.0
34 0.3 0.5
No. of samples = 18 17 18 14 14
Mean = 0.53 0.99 1.58 2.27 2.54
S.e. of the mean = 0.09 0.15 0.22 0.31 0.32
No. of
paired samples 13 13 11 12
To investigate whether the NAG:AG ratio stabi-
lised during more prolonged therapy, ratios were
calculated for 15 of the patients who received
treatment for more than four months duration
(Table V). Although this analysis suggested that the
ratio stabilised only after six months of treatment,
alterations in the NAG:AG ratio failed to achieve
statistical significance using paired t-tests.
Discussion
There has been only one previous study which has
investigated the serum drug levels in post-
menopausal patients with advanced breast cancer
(Murray et al., 1979). This study, using a non-
specific spectrophotometric method noted that the
mean serum AG concentration in seven patients
after 12 weeks of AG (1 g daily) combined with HC
(40mg daily) was 11.5+3.6pgml- ' (mean+s.e.).
Although time intervals between dose and blood
samples were not measured accurately, most
samples were taken 2h after drug administration.
Half-life and clearance rate studies performed in a
further 6 patients at the start of therapy and later
after 6 weeks of treatment demonstrated that the
half-life of AG was shortened significantly and
clearance rate increased significantly after 6 weeks
of treatment. These data were interpreted as sug-
gesting that AG, like glutethimide, may stimulate its
own metabolism through hepatic microsomal en-
zyme induction (Jackson et al., 1978).
In the current study, the mean serum AG con-
centration in 24 patients receiving an identical doseLOW DOSE AMINOGLUTETHIMIDE PHARMACOKINETICS 489
Table III NAG:AG ratios in 24 patients receiving increasing doses of AG (NAG=N-
acetylaminoglutethimide; AG=Aminoglutethimide; HC=hydrocortisone; b.d. =twice
daily).
Dose ofAG (mg)
Patient 62.5 125 250 500 500
No. b.d. b.d. b.d. b.d. b.d. +HC
NAG:AG ratio
1 2.0 0.5 - 0.14
3 0.5 0.46 0.3
4 1.14 0.43
5 0.86 0.35 0.71
7 0.31 0.18 0.24
8 3.5 1.44 0.84 0.40 0.49
9 0.71 0.89 0.26 0.16 0.2
10 2.6 0.58 0.66
12 0.86 0.25 -
15 0.60 0.33 0.15 0.12
16 - 0.38 0.27 0.17
17 0.5 0.31 - 0.15
19 1.75 3.33 0.77 2.42 0.43
21 0.33 0.36 0.23 0.15 0.11
22 0.67 0.31 0.22
23 1.0 0.37 0.43 0.19 0.14
25 2.0 0.83 0.37 0.39
26 0.33 0.24 0.12
29 2.3 1.57
30 5.0 2.67 1.60
31 - 0.7 0.33 0.33
32 - 1.67 0.2 0.2
33 1.5 1.14 0.71 1.03
34 0.43 0.33
No. of samples = 18 17 18 14 14
Mean = 1.43 0.97 0.60 0.44 0.35
S.e. of the mean = 0.29 0.23 0.10 0.16 0.07
No. of
paired samples 13 13 11 12
of AG and HC was 9.09+1.3,ugml-1, after 5
months of therapy. Allowing for the greater mean
time interval between drug administration and col-
lection of blood samples, our results for mean
serum AG concentration, using a high pressure
liquid chromatographic method, are very similar to
those recorded by Murray et al. (1979).
Murray et al. (1979) also suggested that AG can
induce its own metabolism and that induction is
probably complete within one week of starting
therapy. Our observations that serum AG con-
centrations increased in an approximate linear
relationship with increasing dose suggest that if in-
duction occurs then this is completed within the first
month of therapy. However, NAG concentrations
increased significantly more slowly, leading to a fall
in the NAG:AG ratio during therapy, although the
ratio appeared to stabilise after approximately six
months of therapy. The fall in the NAG:AG ratio
during chronic therapy suggests that alteration in
the metabolism of NAG may occur during pro-
longed treatment. The cause of this alteration is not
known, but it may be that the production of NAG
is rate-limited. The metabolism of other com-
pounds, that are acetylated, such as isoniazid, has
been shown to be rate-limited (Thom et al., 1981).
Recently however, a novel metabolite of AG,
hydroxylaminoglutethmide (hydroxyl-AG), has been
described (Jarman et al., 1983). This report sug-
gested that hydroxyl-AG may be an induced meta-
bolite as it is only formed during chronic therapy.
Moreover, the data suggested that hydroxyl-AG
may be formed at the expense of NAG. It is
possible therefore, that the fall in the NAG:AG490 R. STUART-HARRIS et al.
Table IV Time intervals (minutes) between dose and
blood sample in 24 patients receiving increasing doses of
AG. (AG=aminoglutethimide; HC=hydrocortisone; b.d.
twice daily).
Dose ofAG (mg)
Patient 62.5 125 250 500 500
No. b.d. b.d. b.d. b.d. b.d. +HC
Dose - sampling time intervals (min)
1 30 70 65
3 225 285 300
4 270 190
5 285 300 285
7 465 390 420
8 225 188 225 190 178
9 100 135 120 128 120
10 105 105 140
12 360 360 -
15 350 420 420 434
16 105 165 180
17 10 45 - 27
19 333 350 300 240 320
21 345 300 325 340 336
22 300 263 315
23 75 30 75 120 150
25 330 - 300 355 360
26 120 160 165 -
29 360 390 -
30 90 90 30
31 360 360 340
32 225 - 170 158
33 315 225 315 315
34 420 380 -
No. of
samples = 18 17 18 14 14
Mean =219 214 268 241 249
S.e. of the
mean = 128 120 119 119 126
ratio might reflect increasing production of RS-H was in receipt of a Research Fellowship awarded by
hydroxyl-AG. the Clinical Research Committee of the Royal Marsden
Further studies, however, will be necessary to Hospital during this study. We are grateful to Miss S.
confirm that the NAG:AG ratio falls during Beehnick and Mrs L. Carr for help in sample and data
chronic therapy and to establish the mechanism and collection and Miss J. Hood for preparation of the
possible clinical significance of this alteration. manuscript.LOW DOSE AMINOGLUTETHIMIDE PHARMACOKINETICS 491
Table V NAG:AG ratios in 15 patients receiving AG for more than 4 months. Numbers in
parentheses represent the dose-sampling intervals in minutes (NAG=N-acetylaminoglutethimide;
AG=aminoglutethimide).
Months oftherapy
Patient
No. 4 5 6 7 .8
NAG:AG Ratio
7 0.18(390) 0.26(420) 0.21(420)
8 0.40(190) 0.42(200) 0.58(165) 0.52(170)
9 0.89(135) 0.26(120) 0.16(135) 0.15(120) 0.20(120)
10 0.58(105) 0.66(140)
15 0.15(420) 0.18(420) 0.12(420) 0.12(460) 0.12(435)
16 0.36(105) 0.27(165) 0.17(180) 0.23(105)
17 0.23 (30) 0.15 (30) 0.15 (30) 0.13 (20)
19 2.42(240) 0.52(255) 0.40(295) 0.46(300) 0.37(330)
21 0.23(325) 0.15(340) 0.11(290) 0.09(320) 0.13(420)
23 0.15(150) 0.12(320)
25 0.37(355) 0.41(360) 0.38(360)
30 1.82(120) 1.54(105) 1.57(120)
31 0.33(360) 0.28(360) 0.40(330) 0.29(330)
32 0.20(170) 0.20(165) 0.21(195) 0.18(130)
33 0.71(315) 1.31(300) 0.84(330) -
No. of samples = 14 12 11 8 11
Mean =0.63(231) 0.52(266) 0.33(244) 0.20(253) 0.35(227)
S.e. of the mean =0.18 (34) 0.13 (34) 0.07 (36) 0.04 (52) 0.13 (43)
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